• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
MENG Jin,ZHANG Rui,SU Guangzhu,WANG Lu.Research progress of drugs and mechanisms of action to reverse Cetuximab resistance[J].Journal Of Pharmaceutical Research,2025,44(4):377-383,416[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2354times   Download 774次 QR Code for this article
Scan with your phone!
逆转西妥昔单抗耐药的药物及作用机制研究进展
孟瑾1,张瑞2,苏广珠3,王潞3
Font:Larger+|Default|Smaller-
(1.山东第一医科大学药学院,山东 济南 250117;2.济南市精神卫生中心药剂科,山东 济南 250309;3.山东第一医科大学附属中心医院药学部,山东 济南 250013)
摘要:
西妥昔单抗在临床上主要用于结直肠癌、胃癌等消化道肿瘤的治疗。然而,随着临床应用的不断深入,西妥昔单抗的耐药性问题日益凸显,极大限制了其广泛应用。即使西妥昔单抗对患者治疗有效,其缓解期最多持续12~18个月,之后几乎所有患者都会产生继发性耐药,导致治疗失败。因此,深入探讨西妥昔单抗的耐药机制并找到有效的逆转药物,对明确最佳的联合用药及靶向治疗模式、提高结直肠癌等肿瘤的治疗疗效具有重要意义。
关键词:  西妥昔单抗  耐药  逆转耐药  药物作用  分子机制
DOI:10.13506/j.cnki.jpr.2025.04.012
基金项目:山东省自然科学基金面上项目(No.ZR2023MH016);济南市临床医学科技发展计划项目(No.202134050);山东第一医科大学青年科学基金培育资助计划项目(No.202201-136)
Publication Date:April 25, 2025
Research progress of drugs and mechanisms of action to reverse Cetuximab resistance
MENG Jin1,ZHANG Rui2,SU Guangzhu3,WANG Lu3
(1.Department of Pharmacy, Shandong First Medical University, Jinan 250000, China; 2.Department of Pharmacy, Jinan Mental Health Center, Jinan 250309, China; 3.Department of Pharmacy, Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, China)
Abstract:
Cetuximab is mainly used in clinical practice for the treatment of gastrointestinal tumors such as colorectal cancer and gastric cancer. However, with the continuous deepening of clinical applications, the issue of resistance to Cetuximab has become increasingly prominent, greatly limiting its widespread use. Even if patients are effectively treated with Cetuximab, the remission period lasts up to 12-18 months, after which almost all patients develop secondary resistance, leading to treatment failure. Therefore, in-depth exploration of the resistance mechanism of Cetuximab and finding effective reversal drugs are of great significance for clarifying the optimal combination therapy and targeted treatment mode, and improving the therapeutic efficacy of tumors such as colorectal cancer.
Key words:  Cetuximab  Drug resistance  Reversal of drug resistance  Drug action  Molecular mechanism
Today's Visits:488    Total Visits:2383203
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.